Oligonucleotide Therapeutics and Delivery Conference 2021

Oligonucleotide therapeutics - the emerging medicine class - are harnessing the therapeutic benefit of targeting genetic material via antisense, mRNA, RNAi, saRNA and siRNA. Their market growth: CAGR of 13.7% projected to reach USD 8.2 billion by 2024 is driven by their potential to provide more efficacious and less toxic alternatives to small molecules. They bring about the ability to affect targets that have been considered "non-draggable". Heavy investments in oligonucleotide therapeutic discovery have created an emerging market need for drug delivery technologies.

SMi's inaugural Oligonucleotide Therapeutics and Delivery conference is here to keep you updated. By bringing together leading representatives of pharmaceutical, biotechnology and academic institutions, the 2-day conference will provide first-hand information on the latest clinical trial candidates and a platform for exchanging ideas for tackling the biggest challenge: DELIVERY. From optimizing particle size to choosing the right nanocarrier systems, the conference will address delivery to non-hepatocyte cells such as cancerous tissues and overview the most successful platforms. Discussions will be centered around improving targeted therapy uniting the field's biggest players to share their opinions.

Established on the success of our RNA Therapeutics series, we look forward to welcoming you at Oligonucleotide Therapeutics and Delivery to join the conversation around maximizing the potential of oligo-based treatments.

Benefits of attending:

- Gain first-hand insight into oligonucleotide therapy clinical success of the latest developments for novel agents
- Listen to case studies presenting the latest candidates undergoing pre-clinical and clinical research
- Deepen your understanding of crucial delivery methods and available platforms for non-hepatocytic delivery
- Explore the chemistry of oligonucleotide therapeutics and examine novel applications of antisense oligonucleotides in the AstraZeneca Deep Dive
- Engage in the latest innovations of oligonucleotide therapeutics with insights into immunochemotherapeutics, ocular indications and Duchenne Muscular Dystrophy

Plus, an interactive half day pre-conference workshop on Target Discovery for RNA Therapeutics
Workshop Leader: Martin Akerman, Chief Technology Officer, Envisagenics

CHAIR FOR 2021:
Nagy Habib, Professor of Surgery, Imperial College, Co-founder MiNA therapeutics, Imperial College London

FEATURED 2021 SPEAKERS INCLUDE:

- David Evans, Chief Scientific Officer, Sirnaomics, Inc
- Stefan Vonhoff, VP Chemistry and Manufacturing, NOXXON Pharma AG
- Adrien Weingartner, Principal Scientist, Group Leader Drug Delivery, Silence Therapeutics AG
- Tom Baladi, Postdoctoral Research Fellow, AstraZeneca
- Maria Luisa Pineda, CEO and Co-founder, Envisagenics
- Ekkehard Leberer, Senior Director, R and D Alliance Management, Sanofi
- Michelle Lynn Hall, Senior Director, Novel Therapeutic Modalities, Eli Lilly and Company
- Jimmy Weterings, Principal Scientist, AstraZeneca
- Arthur A Levin, Chief Scientific Officer, Avidity Biosciences Inc
- Meiling LI, Senior Scientist, F. Hoffmann-La Roche Ltd

Who should attend:
Executives, Directors, VPs, Heads, Principals, Managers of:
- RNA Biology/Discovery
- Novel Therapeutic Modalities
- Innovation Technologies
- C-level Scientific Executives
- Formulation and Drug Delivery
- Clinical Research and Development
- Cell Biology

EARLY-BIRD RATES:
- BOOK BY 28TH MAY AND SAVE £200 
- BOOK BY 30TH JUNEAND SAVE £100 

Additional Contact Info:
T: +44 (0)20 7827 6088
E: hsidhu@smi-online.co.uk

LinkedIn: @SMi Pharma
Twitter: #SMiOligonucleotides